Compare ACAD & AUGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACAD | AUGO |
|---|---|---|
| Founded | 1993 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.8B |
| IPO Year | 2000 | 2009 |
| Metric | ACAD | AUGO |
|---|---|---|
| Price | $28.38 | $75.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 3 |
| Target Price | $30.55 | ★ $67.60 |
| AVG Volume (30 Days) | ★ 1.7M | 798.1K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.97% |
| EPS Growth | ★ 69.12 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $726,437,000.00 | N/A |
| Revenue This Year | $18.80 | $91.05 |
| Revenue Next Year | $11.70 | $17.09 |
| P/E Ratio | $141.95 | ★ N/A |
| Revenue Growth | ★ 40.45 | N/A |
| 52 Week Low | $19.69 | $26.63 |
| 52 Week High | $29.85 | $110.32 |
| Indicator | ACAD | AUGO |
|---|---|---|
| Relative Strength Index (RSI) | 61.99 | 67.27 |
| Support Level | $25.00 | $71.04 |
| Resistance Level | N/A | $77.01 |
| Average True Range (ATR) | 0.95 | 3.16 |
| MACD | 0.09 | 2.27 |
| Stochastic Oscillator | 66.04 | 87.75 |
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Aura Minerals Inc is a mid-tier gold and copper production company focused on the development and operation of gold and base metal projects in the Americas. The company's operating segments include: Minosa Mine, Apoena Mine, the Aranzazu Mine, Almas Mine, Borborema Mine and Serra Grande Mine. It derives maximum revenue from Aranzazu Mine. The company's growth projects include: Matupa in Brazil, and Era Dorada in Guatemala. whereas its exploration projects include: Carajas, in Brazil, and Tolda Fria in Colombia.